Evolent Health Analyst Price Targets - Benzinga

Evolent Health Inc

EVHNYSE

Trade with Public

Trade with Public

$4.59

-0.0019-0.04%

Ult. Agg.: Aug 28, 8:28 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Evolent Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Evolent Health (EVH).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

3S.Buy

11Buy

2Hold

Consensus RatingBuy# Analysts16Avg. Consensus PT$11Upside to Avg. PT+133.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	JP Morgan	John Stansel	PT Raise	Overweight	$5→$6
Aug 17, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$5→$6
Aug 12, 2026	Truist Securities	Jailendra Singh	PT Cut	Hold	$7→$6
Aug 11, 2026	Citigroup	Daniel Grosslight	Upgrade	Neutral→Buy	$7→$6
Aug 10, 2026	Canaccord Genuity	Richard Close	PT Cut	Buy	$7→$6
Jul 28, 2026	TD Cowen	Charles Rhyee	PT Cut	Buy	$8→$5
Jul 23, 2026	Citigroup	Daniel Grosslight	Downgrade	Buy→Neutral	$6→$7
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$6→$7
Jun 30, 2026	Truist Securities	Jailendra Singh	Downgrade	Buy→Hold	$7
Jun 12, 2026	Truist Securities	Jailendra Singh	PT Raise	Buy	$6→$7
May 15, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$6
May 12, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$6
May 7, 2026	Needham	Matthew Shea	PT Raise	Buy	$4→$5
Mar 2, 2026	Oppenheimer	Michael Wiederhorn	PT Cut	Outperform	$12→$6
Feb 26, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$6→$4
Feb 26, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$10→$5
Feb 26, 2026	Truist Securities	Jailendra Singh	PT Cut	Buy	$10→$6
Feb 25, 2026	Needham	Matthew Shea	PT Cut	Buy	$15→$4
Feb 25, 2026	RBC Capital	Ryan Halsted	PT Cut	Sector Perform	$5→$3
Feb 25, 2026	Keybanc	Matthew Gillmor	Downgrade	Overweight→Sector Weight	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6

JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6

TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6

Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5

TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $8 to $5.

Benzinga Newsdesk